Bristol-Myers Squibb Company said the ongoing phase III CheckMate-227 study met its co-primary endpoint of progression-free survival with the Opdivo (nivolumab) plus Yervoy (ipilimumab) combination versus chemotherapy in first-line advanced non-small cell lung cancer patients whose tumors have high (≥10 mutations/megabase, mut/mb) tumor mutation burden, regardless of PD-L1 expression.
Tyme Technologies Inc. announced efficacy and safety data from an ongoing phase II trial of SM-88 in patients with non-metastatic, biochemical-recurrent prostate cancer.
Novartis has announced updated results from the pivotal ELIANA clinical trial of Kymriah (tisagenlecleucel), formerly CTL019, in relapsed or refractory (pediatric and young adult patients with B-cell acute lymphoblastic leukemia have been published in The New England Journal of Medicine. New data include longer-term follow-up and efficacy in 75 infused patients, analysis of expansion and persistence of Kymriah, and longer-term safety.
Bristol-Myers Squibb Co. announced new data from a cohort of the phase II CheckMate -142 trial evaluating Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment of patients with DNA mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer.
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.
A study published in the Journal of the National Cancer Institute indicates that screening the general population for mutations in specific genes is a more cost-effective way to detect people at risk and prevents more breast and ovarian cancers compared to only screening patients with a personal or family history of these diseases.
An international team, led by researchers at the University of California San Diego School of Medicine, has developed a genetic tool for predicting age of onset of aggressive prostate cancer.
Exelixis Inc. and Ipsen announced detailed results of the pivotal phase III CELESTIAL trial in patients with previously treated advanced hepatocellular carcinoma, which will be presented in a late-breaking oral session at the 2018 ASCO-GI Symposium.
Specialty diagnostics company Precipio Inc. announced preliminary data from an ongoing study on the impact of academic pathology expertise on diagnostic accuracy.
Researchers at UT Southwestern's Simmons Cancer Center have shown that RAS molecules act in pairs, known as dimers, to cause cancer, findings that could help guide them to a treatment.
